Kush Parmar - Net Worth and Insider Trading

Kush Parmar Net Worth

The estimated net worth of Kush Parmar is at least $116 Million dollars as of 2024-12-27. Kush Parmar is the Director, 10% Owner of Entrada Therapeutics Inc and owns about 5,290,736 shares of Entrada Therapeutics Inc (TRDA) stock worth over $94 Million. Kush Parmar is the Director, 10% Owner of Akouos Inc and owns about 982,453 shares of Akouos Inc (AKUS) stock worth over $13 Million. Kush Parmar is also the Director, 10% Owner of Vor Biopharma Inc and owns about 6,361,723 shares of Vor Biopharma Inc (VOR) stock worth over $5 Million. Besides these, Kush Parmar also holds Rallybio Corp (RLYB) , Homology Medicines Inc (FIXX) . Details can be seen in Kush Parmar's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Kush Parmar has not made any transactions after 2023-03-07 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Kush Parmar

Kush Parmar Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Kush Parmar owns 15 companies in total, including 5:01 Acquisition Corp (FVAM) , Aprea Therapeutics Inc (APRE) , and Akouos Inc (AKUS) among others .

Click here to see the complete history of Kush Parmar’s form 4 insider trades.

Insider Ownership Summary of Kush Parmar

Ticker	Comapny	Transaction Date	Type of Owner
FVAM	5:01 Acquisition Corp	2020-10-13	director & 10 percent owner & Co-CEO
APRE	Aprea Therapeutics Inc	2019-10-07	10 percent owner
AKUS	Akouos Inc	2020-12-29	director & 10 percent owner
		2020-12-22	director & 10 percent owner
		2019-10-24	10 percent owner
		2018-09-26	director
		2017-11-16	director
		2018-06-08	director
		2021-04-22	10 percent owner
		2021-11-02	director & 10 percent owner
		2023-03-07	director & 10 percent owner
		2021-11-16	director & 10 percent owner
		2022-01-06	10 percent owner
		2023-02-23	10 percent owner
		2023-08-18	10 percent owner

Kush Parmar Latest Holdings Summary

Kush Parmar currently owns a total of 5 stocks. Among these stocks, Kush Parmar owns 5,290,736 shares of Entrada Therapeutics Inc (TRDA) as of November 2, 2021, with a value of $94 Million and a weighting of 81.04%. Kush Parmar owns 982,453 shares of Akouos Inc (AKUS) as of December 29, 2020, with a value of $13 Million and a weighting of 11.27%. Kush Parmar also owns 6,361,723 shares of Vor Biopharma Inc (VOR) as of November 16, 2021, with a value of $5 Million and a weighting of 4.6%. The other 2 stocks Rallybio Corp (RLYB) , Homology Medicines Inc (FIXX) have a combined weighting of 3.09% among all his current holdings.

Latest Holdings of Kush Parmar

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
TRDA	Entrada Therapeutics Inc	2021-11-02	5,290,736	17.74	93,857,657
AKUS	Akouos Inc	2020-12-29	982,453	13.29	13,056,800
VOR	Vor Biopharma Inc	2021-11-16	6,361,723	0.84	5,331,124
RLYB	Rallybio Corp	2023-03-07	3,630,724	0.92	3,340,266
FIXX	Homology Medicines Inc	2020-12-22	251,996	0.93	235,541

Holding Weightings of Kush Parmar

Kush Parmar Form 4 Trading Tracker

According to the SEC Form 4 filings, Kush Parmar has made a total of 1 transactions in Entrada Therapeutics Inc (TRDA) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Entrada Therapeutics Inc is the acquisition of 250,000 shares on November 2, 2021, which cost Kush Parmar around $5 Million.

According to the SEC Form 4 filings, Kush Parmar has made a total of 2 transactions in Akouos Inc (AKUS) over the past 5 years, including 1 buys and 1 sells. The most-recent trade in Akouos Inc is the sale of 470,000 shares on December 29, 2020, which brought Kush Parmar around $8 Million.

According to the SEC Form 4 filings, Kush Parmar has made a total of 2 transactions in Vor Biopharma Inc (VOR) over the past 5 years, including 1 buys and 1 sells. The most-recent trade in Vor Biopharma Inc is the sale of 330,706 shares on November 16, 2021, which brought Kush Parmar around $5 Million.

More details on Kush Parmar's insider transactions can be found in the Insider Trading History of Kush Parmar table.

Insider Trading History of Kush Parmar

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Kush Parmar Trading Performance

GuruFocus tracks the stock performance after each of Kush Parmar's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Kush Parmar is -24.69%. GuruFocus also compares Kush Parmar's trading performance to market benchmark return within the same time period. The performance of stocks bought by Kush Parmar within 3 months outperforms 1 times out of 4 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Kush Parmar's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Kush Parmar

Average Return

Average return per transaction

Outperforming Transactions

0 out of 4 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	-9.58
Relative Return to S&P 500(%)	-11.09

Kush Parmar Ownership Network

Ownership Network List of Kush Parmar

No Data

Ownership Network Relation of Kush Parmar

Kush Parmar Owned Company Details

What does 5:01 Acquisition Corp do?

Who are the key executives at 5:01 Acquisition Corp?

Kush Parmar is the director & 10 percent owner & Co-CEO of 5:01 Acquisition Corp. Other key executives at 5:01 Acquisition Corp include director & 10 percent owner & Co-CEO Andrew J. Schwab , 10 percent owner 5am Ventures Vi, L.p. , and 10 percent owner 5:01 Acquisition Llc .

5:01 Acquisition Corp (FVAM) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of 5:01 Acquisition Corp (FVAM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of 5:01 Acquisition Corp (FVAM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

5:01 Acquisition Corp (FVAM)'s detailed insider trading history can be found in Insider Trading Tracker table.

5:01 Acquisition Corp Insider Transactions

No Available Data

What does Aprea Therapeutics Inc do?

Who are the key executives at Aprea Therapeutics Inc?

Kush Parmar is the 10 percent owner of Aprea Therapeutics Inc. Other key executives at Aprea Therapeutics Inc include President & CEO Oren Gilad , SrVP/CFO/Prin. Fin &Acctg. Off John P. Hamill , and director & President & CEO Christian S Schade .

Aprea Therapeutics Inc (APRE) Insider Trades Summary

Over the past 18 months, Kush Parmar made no insider transaction in Aprea Therapeutics Inc (APRE). Other recent insider transactions involving Aprea Therapeutics Inc (APRE) include a net purchase of 3,900 shares made by Oren Gilad , a net purchase of 23,728 shares made by Marc Duey , and a net purchase of 1,510 shares made by John P. Hamill .

In summary, during the past 3 months, insiders sold 6,462 shares of Aprea Therapeutics Inc (APRE) in total and bought 42,590 shares, with a net purchase of 36,128 shares. During the past 18 months, 6,462 shares of Aprea Therapeutics Inc (APRE) were sold and 59,320 shares were bought by its insiders, resulting in a net purchase of 52,858 shares.

Aprea Therapeutics Inc (APRE)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aprea Therapeutics Inc Insider Transactions

No Available Data

What does Akouos Inc do?

Who are the key executives at Akouos Inc?

Kush Parmar is the director & 10 percent owner of Akouos Inc. Other key executives at Akouos Inc include 10 percent owner Kearny Acquisition Corp , 10 percent owner Lilly Eli & Co , and Chief Operating Officer Jennifer Anne Wellman .

Akouos Inc (AKUS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Akouos Inc (AKUS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Akouos Inc (AKUS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Akouos Inc (AKUS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Akouos Inc Insider Transactions

No Available Data

What does Homology Medicines Inc do?

Who are the key executives at Homology Medicines Inc?

Kush Parmar is the director & 10 percent owner of Homology Medicines Inc. Other key executives at Homology Medicines Inc include director & President & CEO Arthur Tzianabos , See Remarks Paul Alloway , and Chief Scientific Officer Albert Seymour .

Homology Medicines Inc (FIXX) Insider Trades Summary

Over the past 18 months, Kush Parmar made no insider transaction in Homology Medicines Inc (FIXX). Other recent insider transactions involving Homology Medicines Inc (FIXX) include a net sale of 1,952 shares made by Julie Jordan , a net sale of 13,037 shares made by Arthur Tzianabos , and a net sale of 7,280 shares made by Paul Alloway .

In summary, during the past 3 months, insiders sold 0 shares of Homology Medicines Inc (FIXX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 1,413 shares of Homology Medicines Inc (FIXX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,413 shares.

Homology Medicines Inc (FIXX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Homology Medicines Inc Insider Transactions

No Available Data

What does Cabaletta Bio Inc do?

Who are the key executives at Cabaletta Bio Inc?

Kush Parmar is the 10 percent owner of Cabaletta Bio Inc. Other key executives at Cabaletta Bio Inc include EVP & Science & Technology Gwendolyn Binder , director & President & CEO Steven Nichtberger , and Chief Financial Officer Anup Marda .

Cabaletta Bio Inc (CABA) Insider Trades Summary

Over the past 18 months, Kush Parmar made no insider transaction in Cabaletta Bio Inc (CABA). Other recent insider transactions involving Cabaletta Bio Inc (CABA) include a net sale of 77,000 shares made by Gwendolyn Binder ,

In summary, during the past 3 months, insiders sold 0 shares of Cabaletta Bio Inc (CABA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 77,000 shares of Cabaletta Bio Inc (CABA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 77,000 shares.

Cabaletta Bio Inc (CABA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cabaletta Bio Inc Insider Transactions

No Available Data

What does Arvinas Inc do?

Who are the key executives at Arvinas Inc?

Kush Parmar is the director of Arvinas Inc. Other key executives at Arvinas Inc include Chief Accounting Officer David K Loomis , Chief Medical Officer Ronald Peck , and Chief Financial Officer Sean A Cassidy .

Arvinas Inc (ARVN) Insider Trades Summary

Over the past 18 months, Kush Parmar made no insider transaction in Arvinas Inc (ARVN). Other recent insider transactions involving Arvinas Inc (ARVN) include a net sale of 3,023 shares made by Ronald Peck , a net sale of 5,196 shares made by John G Houston , and a net sale of 1,702 shares made by Sean A Cassidy .

In summary, during the past 3 months, insiders sold 460 shares of Arvinas Inc (ARVN) in total and bought 0 shares, with a net sale of 460 shares. During the past 18 months, 12,082 shares of Arvinas Inc (ARVN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 12,082 shares.

Arvinas Inc (ARVN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Arvinas Inc Insider Transactions

No Available Data

What does scPharmaceuticals Inc do?

Who are the key executives at scPharmaceuticals Inc?

Kush Parmar is the director of scPharmaceuticals Inc. Other key executives at scPharmaceuticals Inc include 10 percent owner Orbimed Advisors Llc , 10 percent owner 5am Partners Iv, Llc , and director & President and CEO John H Tucker .

scPharmaceuticals Inc (SCPH) Insider Trades Summary

Over the past 18 months, Kush Parmar made no insider transaction in scPharmaceuticals Inc (SCPH). Other recent insider transactions involving scPharmaceuticals Inc (SCPH) include a net purchase of 500,000 shares made by Orbimed Advisors Llc ,

In summary, during the past 3 months, insiders sold 0 shares of scPharmaceuticals Inc (SCPH) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of scPharmaceuticals Inc (SCPH) were sold and 500,000 shares were bought by its insiders, resulting in a net purchase of 500,000 shares.

scPharmaceuticals Inc (SCPH)'s detailed insider trading history can be found in Insider Trading Tracker table.

scPharmaceuticals Inc Insider Transactions

No Available Data

What does Audentes Therapeutics Inc do?

Who are the key executives at Audentes Therapeutics Inc?

Kush Parmar is the director of Audentes Therapeutics Inc. Other key executives at Audentes Therapeutics Inc include President and COO Natalie C. Holles , SVP & Chief Medical Officer Edward R. Conner , and Executive Vice President & CFO Thomas P Soloway .

Audentes Therapeutics Inc (BOLD) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Audentes Therapeutics Inc (BOLD) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Audentes Therapeutics Inc (BOLD) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Audentes Therapeutics Inc (BOLD)'s detailed insider trading history can be found in Insider Trading Tracker table.

Audentes Therapeutics Inc Insider Transactions

No Available Data

What does IPI Legacy Liquidation Co do?

Who are the key executives at IPI Legacy Liquidation Co?

Kush Parmar is the 10 percent owner of IPI Legacy Liquidation Co. Other key executives at IPI Legacy Liquidation Co include 10 percent owner Vivo Capital Fund Viii, L.p. , CFO Michael Wayne Kalb , and VP & Controller & Interim CFO Rajiv Amin .

IPI Legacy Liquidation Co (IMPLQ) Insider Trades Summary

Over the past 18 months, Kush Parmar made no insider transaction in IPI Legacy Liquidation Co (IMPLQ). Other recent insider transactions involving IPI Legacy Liquidation Co (IMPLQ) include a net sale of 575,000 shares made by Vivo Capital Fund Viii, L.p. ,

In summary, during the past 3 months, insiders sold 0 shares of IPI Legacy Liquidation Co (IMPLQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 575,000 shares of IPI Legacy Liquidation Co (IMPLQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 575,000 shares.

IPI Legacy Liquidation Co (IMPLQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

IPI Legacy Liquidation Co Insider Transactions

No Available Data

What does Entrada Therapeutics Inc do?

Who are the key executives at Entrada Therapeutics Inc?

Kush Parmar is the director & 10 percent owner of Entrada Therapeutics Inc. Other key executives at Entrada Therapeutics Inc include 10 percent owner Mpm Bioventures 2018, L.p. , 10 percent owner Mpm Bioventures 2014, L.p. , and Chief Scientific Officer Natarajan Sethuraman .

Entrada Therapeutics Inc (TRDA) Insider Trades Summary

Over the past 18 months, Kush Parmar made no insider transaction in Entrada Therapeutics Inc (TRDA). Other recent insider transactions involving Entrada Therapeutics Inc (TRDA) include a net sale of 12,900 shares made by Dipal Doshi , a net sale of 80,157 shares made by Natarajan Sethuraman , and a net sale of 47,126 shares made by Kory James Wentworth .

In summary, during the past 3 months, insiders sold 142,900 shares of Entrada Therapeutics Inc (TRDA) in total and bought 0 shares, with a net sale of 142,900 shares. During the past 18 months, 297,371 shares of Entrada Therapeutics Inc (TRDA) were sold and 45,368 shares were bought by its insiders, resulting in a net sale of 252,003 shares.

Entrada Therapeutics Inc (TRDA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Entrada Therapeutics Inc Insider Transactions

No Available Data

What does Rallybio Corp do?

Who are the key executives at Rallybio Corp?

Kush Parmar is the director & 10 percent owner of Rallybio Corp. Other key executives at Rallybio Corp include 10 percent owner 5am Partners V, Llc , See Remarks Jonathan I Lieber , and 10 percent owner Viking Global Investors Lp .

Rallybio Corp (RLYB) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Rallybio Corp (RLYB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Rallybio Corp (RLYB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Rallybio Corp (RLYB)'s detailed insider trading history can be found in Insider Trading Tracker table.

Rallybio Corp Insider Transactions

No Available Data

What does Vor Biopharma Inc do?

Who are the key executives at Vor Biopharma Inc?

Kush Parmar is the director & 10 percent owner of Vor Biopharma Inc. Other key executives at Vor Biopharma Inc include Chief Medical Officer Eyal C. Attar , 10 percent owner 5am Ventures Vi, L.p. , and director & 10 percent owner Ra Capital Healthcare Fund Lp .

Vor Biopharma Inc (VOR) Insider Trades Summary

Over the past 18 months, Kush Parmar made no insider transaction in Vor Biopharma Inc (VOR). Other recent insider transactions involving Vor Biopharma Inc (VOR) include a net sale of 14,645 shares made by Eyal C. Attar ,

In summary, during the past 3 months, insiders sold 0 shares of Vor Biopharma Inc (VOR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 14,645 shares of Vor Biopharma Inc (VOR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 14,645 shares.

Vor Biopharma Inc (VOR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Vor Biopharma Inc Insider Transactions

No Available Data

What does CinCor Pharma Inc do?

Who are the key executives at CinCor Pharma Inc?

Kush Parmar is the 10 percent owner of CinCor Pharma Inc. Other key executives at CinCor Pharma Inc include director & 10 percent owner James Healy , 10 percent owner Sofinnova Management X-a, L.l.c. , and EVP & Chief Financial Officer Michael Wayne Kalb .

CinCor Pharma Inc (CINC) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of CinCor Pharma Inc (CINC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of CinCor Pharma Inc (CINC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

CinCor Pharma Inc (CINC)'s detailed insider trading history can be found in Insider Trading Tracker table.

CinCor Pharma Inc Insider Transactions

No Available Data

What does Enliven Therapeutics Inc do?

Who are the key executives at Enliven Therapeutics Inc?

Kush Parmar is the 10 percent owner of Enliven Therapeutics Inc. Other key executives at Enliven Therapeutics Inc include Chief Financial Officer Benjamin Hohl , director & President and CEO Samuel Kintz , and Chief Operating Officer Anish Patel .

Enliven Therapeutics Inc (ELVN) Insider Trades Summary

Over the past 18 months, Kush Parmar made no insider transaction in Enliven Therapeutics Inc (ELVN). Other recent insider transactions involving Enliven Therapeutics Inc (ELVN) include a net sale of 93,564 shares made by Benjamin Hohl , a net sale of 240,342 shares made by Samuel Kintz , and a net sale of 239,847 shares made by Joseph P Lyssikatos .

In summary, during the past 3 months, insiders sold 157,819 shares of Enliven Therapeutics Inc (ELVN) in total and bought 0 shares, with a net sale of 157,819 shares. During the past 18 months, 4,860,959 shares of Enliven Therapeutics Inc (ELVN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 4,860,959 shares.

Enliven Therapeutics Inc (ELVN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Enliven Therapeutics Inc Insider Transactions

No Available Data

What does Skye Bioscience Inc do?

Who are the key executives at Skye Bioscience Inc?

Kush Parmar is the 10 percent owner of Skye Bioscience Inc. Other key executives at Skye Bioscience Inc include Chief Financial Officer Kaitlyn Melanie Arsenault , 10 percent owner 5am Partners Vii, Llc , and director & 10 percent owner Andrew J. Schwab .

Skye Bioscience Inc (SKYE) Insider Trades Summary

Over the past 18 months, Kush Parmar made no insider transaction in Skye Bioscience Inc (SKYE). Other recent insider transactions involving Skye Bioscience Inc (SKYE) include a net purchase of 5,389,737 shares made by 5am Partners Vii, Llc , a net purchase of 1,679,090 shares made by Punit Dhillon , and a net sale of 266,337 shares made by Andrew J. Schwab .

In summary, during the past 3 months, insiders sold 232,431 shares of Skye Bioscience Inc (SKYE) in total and bought 0 shares, with a net sale of 232,431 shares. During the past 18 months, 765,105 shares of Skye Bioscience Inc (SKYE) were sold and 5,663,122 shares were bought by its insiders, resulting in a net purchase of 4,898,017 shares.

Skye Bioscience Inc (SKYE)'s detailed insider trading history can be found in Insider Trading Tracker table.

Skye Bioscience Inc Insider Transactions

No Available Data

Kush Parmar Mailing Address

Above is the net worth, insider trading, and ownership report for Kush Parmar. You might contact Kush Parmar via mailing address: C/o 5am Ventures, 501 2nd Street, Suite 350, San Francisco Ca 94107.

Discussions on Kush Parmar

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.